{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:43:24Z","timestamp":1790289804441,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,17]]},"DOI":"10.7759\/cureus.75902","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T02:12:27Z","timestamp":1734487947000},"source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of Direct-Acting Antivirals Versus Interferon-Based Therapy in Chronic Hepatitis C Infection"],"prefix":"10.7759","author":[{"given":"Ratna","family":"Chowdhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wardah","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taranpreet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdur","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nida F","family":"Daterdiwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varaidzo","family":"Mkosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumikala","family":"Limbu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Alliza","family":"Bukhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afif","family":"Ramadhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muath M","family":"Dabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Shehryar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramadan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Hepatitis C. (2024). Accessed. October 15, 2024: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/2040622310384308","article-title":"Pegylated interferon and ribavirin treatment for hepatitis C virus infection","volume":"2","author":"Palumbo E","year":"2011","unstructured":"Palumbo E. Pegylated interferon and ribavirin treatment for hepatitis C virus infection. Ther Adv Chronic Dis. 2011, 2:39-45. 10.1177\/2040622310384308","journal-title":"Ther Adv Chronic Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13673","article-title":"Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?","volume":"38","author":"Asselah T","year":"2018","unstructured":"Asselah T, Marcellin P, Schinazi RF. Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?. Liver Int. 2018, 38:7-13. 10.1111\/liv.13673","journal-title":"Liver Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000433594","article-title":"The new era of interferon-free treatment of chronic hepatitis C","volume":"31","author":"Solbach P","year":"2015","unstructured":"Solbach P, Wedemeyer H. The new era of interferon-free treatment of chronic hepatitis C. Viszeralmedizin. 2015, 31:290-296. 10.1159\/000433594","journal-title":"Viszeralmedizin"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062195","article-title":"Outcomes and follow-up after hepatitis C eradication with direct-acting antivirals","volume":"12","author":"Lynch EN","year":"2023","unstructured":"Lynch EN, Russo FP. Outcomes and follow-up after hepatitis C eradication with direct-acting antivirals. J Clin Med. 2023, 12:2195. 10.3390\/jcm12062195","journal-title":"J Clin Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5195\/jmla.2018.345","article-title":"The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review","volume":"106","author":"Eriksen MB","year":"2018","unstructured":"Eriksen MB, Frandsen TF. The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review. J Med Libr Assoc. 2018, 106:420-431. 10.5195\/jmla.2018.345","journal-title":"J Med Libr Assoc"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i12.3418","article-title":"Daclatasvir vs telaprevir plus peginterferon alfa\/ribavirin for hepatitis C virus genotype 1","volume":"22","author":"Jacobson I","year":"2016","unstructured":"Jacobson I, Zeuzem S, Flisiak R, et al.. Daclatasvir vs telaprevir plus peginterferon alfa\/ribavirin for hepatitis C virus genotype 1. World J Gastroenterol. 2016, 22:3418-3431. 10.3748\/wjg.v22.i12.3418","journal-title":"World J Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz E","year":"2013","unstructured":"Lawitz E, Mangia A, Wyles D, et al.. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013, 368:1878-1887. 10.1056\/NEJMoa1214853","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.07.050","article-title":"Efficacy and safety of elbasvir\/grazoprevir and sofosbuvir\/pegylated interferon\/ribavirin: a phase III randomized controlled trial","volume":"65","author":"Sperl J","year":"2016","unstructured":"Sperl J, Horvath G, Halota W, et al.. Efficacy and safety of elbasvir\/grazoprevir and sofosbuvir\/pegylated interferon\/ribavirin: a phase III randomized controlled trial. J Hepatol. 2016, 65:1112-1119. 10.1016\/j.jhep.2016.07.050","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.109309","article-title":"Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial","volume":"310","author":"Osinusi A","year":"2013","unstructured":"Osinusi A, Meissner EG, Lee YJ, et al.. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013, 310:804-811. 10.1001\/jama.2013.109309","journal-title":"JAMA"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13109","article-title":"Efficacy and safety of ombitasvir\/paritaprevir\/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis","volume":"26","author":"Poordad F","year":"2019","unstructured":"Poordad F, Sedghi S, Pockros PJ, et al.. Efficacy and safety of ombitasvir\/paritaprevir\/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis. J Viral Hepat. 2019, 26:1027-1030. 10.1111\/jvh.13109","journal-title":"J Viral Hepat"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.06.007","article-title":"Sofosbuvir in combination with daclatasvir or simeprevir for 12\u00a0weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial","volume":"25","author":"Pott-Junior H","year":"2019","unstructured":"Pott-Junior H, Bricks G, Grandi G, Figueiredo SJ, Castelo FA. Sofosbuvir in combination with daclatasvir or simeprevir for 12\u00a0weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial. Clin Microbiol Infect. 2019, 25:365-371. 10.1016\/j.cmi.2018.06.007","journal-title":"Clin Microbiol Infect"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.12.027","article-title":"The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis","volume":"148","author":"Pearlman BL","year":"2015","unstructured":"Pearlman BL, Ehleben C, Perrys M. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis. Gastroenterology. 2015, 148:762.e2-770.e2. 10.1053\/j.gastro.2014.12.027","journal-title":"Gastroenterology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz E","year":"2014","unstructured":"Lawitz E, Sulkowski MS, Ghalib R, et al.. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014, 384:1756-1765. 10.1016\/S0140-6736(14)61036-9","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30001-2","article-title":"Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial","volume":"1","author":"Asselah T","year":"2016","unstructured":"Asselah T, H\u00e9zode C, Qaqish RB, et al.. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. Lancet Gastroenterol Hepatol. 2016, 1:25-35. 10.1016\/S2468-1253(16)30001-2","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60247-0","article-title":"Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial","volume":"381","author":"Kowdley KV","year":"2013","unstructured":"Kowdley KV, Lawitz E, Crespo I, et al.. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet (London, England). 2013, 381:2100-2107. 10.1016\/S0140-6736(13)60247-0","journal-title":"Lancet (London, England)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2301291","article-title":"Systematic review with meta-analysis: efficacy and safety of direct-acting antivirals for chronic hepatitis C genotypes 5 and 6","volume":"2019","author":"Due OT","year":"2019","unstructured":"Due OT, Chaikledkaew U, Genuino AJ, Sobhonslidsuk A, Thakkinstian A. Systematic review with meta-analysis: efficacy and safety of direct-acting antivirals for chronic hepatitis C genotypes 5 and 6. Biomed Res Int. 2019, 2019:2301291. 10.1155\/2019\/2301291","journal-title":"Biomed Res Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246594","article-title":"An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease","volume":"16","author":"Majd Jabbari S","year":"2021","unstructured":"Majd Jabbari S, Maajani K, Merat S, Poustchi H, Sepanlou SG. An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease. PLoS One. 2021, 16:e0246594. 10.1371\/journal.pone.0246594","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002173","article-title":"Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase","volume":"33","author":"Hayes KN","year":"2021","unstructured":"Hayes KN, Burkard T, Weiler S, Tadrous M, Burden AM. Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase. Eur J Gastroenterol Hepatol. 2021, 33:e1017-e1021. 10.1097\/MEG.0000000000002173","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012143.pub3","article-title":"Direct-acting antivirals for chronic hepatitis C","volume":"9","author":"Jakobsen JC","year":"2017","unstructured":"Jakobsen JC, Nielsen EE, Feinberg J, et al.. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev. 2017, 9:CD012143. 10.1002\/14651858.CD012143.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa144","article-title":"Evaluation of sustained virologic response as a relevant surrogate endpoint for long-term outcomes of hepatitis C virus infection","volume":"72","author":"Krassenburg LA","year":"2021","unstructured":"Krassenburg LA, Zanjir WR, Georgie F, Stotland E, Janssen HL, Hansen BE, Feld JJ. Evaluation of sustained virologic response as a relevant surrogate endpoint for long-term outcomes of hepatitis C virus infection. Clin Infect Dis. 2021, 72:780-786. 10.1093\/cid\/ciaa144","journal-title":"Clin Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2016.0052","article-title":"Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study","volume":"23","author":"Seo KI","year":"2017","unstructured":"Seo KI, Yun BC, Li WJ, Lee SU, Han BH, Park ET. Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study. Clin Mol Hepatol. 2017, 23:74-79. 10.3350\/cmh.2016.0052","journal-title":"Clin Mol Hepatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i4.1684","article-title":"Hepatitis C virus prevalence and genotype distribution in Pakistan: comprehensive review of recent data","volume":"22","author":"Umer M","year":"2016","unstructured":"Umer M, Iqbal M. Hepatitis C virus prevalence and genotype distribution in Pakistan: comprehensive review of recent data. World J Gastroenterol. 2016, 22:1684-1700. 10.3748\/wjg.v22.i4.1684","journal-title":"World J Gastroenterol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_679_15","article-title":"Newer direct-acting antivirals for hepatitis C virus infection: perspectives for India","volume":"146","author":"Gupta V","year":"2017","unstructured":"Gupta V, Kumar A, Sharma P, Arora A. Newer direct-acting antivirals for hepatitis C virus infection: perspectives for India. Indian J Med Res. 2017, 146:23-33. 10.4103\/ijmr.IJMR_679_15","journal-title":"Indian J Med Res"}],"updated-by":[{"DOI":"10.7759\/cureus.r173","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"record-id":"63783"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/312266-outcomes-of-direct-acting-antivirals-versus-interferon-based-therapy-in-chronic-hepatitis-c-infection","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T02:12:29Z","timestamp":1734487949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/312266-outcomes-of-direct-acting-antivirals-versus-interferon-based-therapy-in-chronic-hepatitis-c-infection"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.75902","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,17]]}}}